Company intelligence / Profile preview

VIVUS

Ownership: Public · VVUS
Development stage: Commercial

Overview

VIVUS is a biopharmaceutical company with commercial-stage products in obesity and sexual health. Its lead product, QSYMIA (phentermine + topiramate), is an FDA-approved chronic weight management medication, and Stendra (avanafil) is an FDA-approved oral treatment for erectile dysfunction. The company continues to develop its pipeline and expand access to its products through digital health partnerships.

Therapeutic areas: Men's HealthEndocrinology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

7 assets

avanafil

Approved

6 more assets in the full pipeline.

Partnerships

Digital health companies (for product access expansion)

Beyond the preview

Go deeper on VIVUS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIVUS.